Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed	Maximum Number Of Patients Agreed	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial
14/YH/0086	147377	RESPOND: Repositionable Lotus Valve System-Post Market Evaluation of Real World Clincial Outcomes	Range Agreed	15	30	Date Agreed	31/12/2015	121	01/10/2016	128	Recruitment Finished
15/LO/1600	182262	A Phase II, Open Label, Randomized Study of GDC-0810 Versus Fulvestrant in Postmenopausal Women with Advanced or Metastatic ER + / HER 2 - Breast Cancer Resistant to Aromatase Inhibitor Therapy	Number Agreed	6	6	Date Agreed	02/03/2018	1	04/10/2016	1	Withdrawn By Sponsor
16/NI/0034	194752	The Medtronic CoreValve™ Evolut R™ FORWARD Study	Number Agreed	5	5	Date Agreed	01/08/2017	11	01/11/2016	11	Recruitment Finished
16/EE/0098	201052	DIASOLVE: A randomised, crossover investigation to evaluate and compare the effectiveness, safety and feasibility of a novel dedicated Over-The-Wire FFR Infusion Microcatheter (HYPEREM™IC) for measuring fractional flow reserve (FFR) using intra-coron	Number Agreed	5	5	Date Agreed	30/11/2016	7	10/11/2016	7	Recruitment Finished
13/NW/0002	114402	Prospective, randomised, controlled investigation comparing the safety and performance of 032-11 Surgical Haemostat 2g Applicator with FLOSEAL? Haemostatic Matrix as an adjunctive haemostat in cardiac surgery and thoracic aortic surgery	Range Agreed	10	32	Date Agreed	28/02/2014	5	01/12/2016	32	Recruitment Finished
13/NI/0138	120046	Portico I Study International long-term follow-up study of patients	Number Agreed	10	10	Date Agreed	30/06/2018	10	01/12/2016	10	Recruitment Finished
13/LO/0821	128690	A Phase 3 Open Label Safety Study of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide SingleTablet Regimen in HIV1 Positive Patients with Mild to Moderate Renal Impairment	Number Agreed	5	5	Not Available / Not Agreed			30/11/2016	1	Recruitment Finished
14/SC/0225	147356	A Phase 3, Randomized, Double-Blind, Switch Study to Evaluate F/TAF in HIV 1 Positive Subjects who are Virologically Suppressed on Regimens containing FTC/TDF	Number Agreed	8	8	Not Available / Not Agreed			21/11/2016	6	Recruitment Finished
14/YH/1269	140294	A Phase 3, OpenLabel, Randomised, Parallel, 2Arm, MultiCenter Study of BMN 673 versus Physician's Choice in Germline BRCA Mutation Subjects with Locally Advanced and/or Metastatic Breast Cancer, Who Have Received No More than 2 Prior Chemotherapy Reg	Range Agreed	1	2	Not Available / Not Agreed			20/04/2017	2	Recruitment Finished
14/YH/0088	151005	Phase I study of KHK2823 in Patients with Acute Myeloid Leukaemia or Myelodysplastic Syndrome	Range Agreed	4	8	Date Agreed	01/02/2017	4	30/06/2017	4	Recruitment Finished
15/NW/0543	181870	A Multicentre, Randomised, Doubleblind, Placebo controlled, Phase 3 Study Evaluating the Efficacy and Safety of Two Doses of Anifrolumab in Adult Subjects with Active Systemic Lupus Erythematosus	Range Agreed	2	3	Date Agreed	30/04/2017	0	30/06/2017	0	Recruitment Finished
16/LO/0586	200579	An Open-Label Study to Evaluate the Efficacy and Safety of Ocrelizumab in Patients with Relapsing Remitting Multiple Sclerosis who have a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment	Number Agreed	4	4	Date Agreed	31/07/2017	0	03/03/2017	0	Recruitment Finished

15/YH/0478	186697	A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Saefty and Efficacy of Obeticholic Acid in Subjects with Nonalcoholic Steatohepatitis	Range Agreed	5	10	Date Agreed	31/10/2016	0	18/08/2017	0	Withdrawn By Host
16/EM/0386	211113	A 12-week double-blind, randomized, multicenter study comparing the efficacy and safety of once monthly subcutaneous 140 mg AMG 334 against placebo in adult episodic migAraine patients who have failed 2-4 prophylactic treatments	Number Agreed	4	4	Date Agreed	22/08/2016	2	03/05/2017	2	Recruitment Finished